EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Safety and Efficacy of Peptide Receptor Radionuclide Therapy for Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Single Center Experience

Leandra Piscopo, Emilia Zampella iD, Fabio Volpe iD, Valeria Gaudieri, Carmela Nappi, Erica Di Donna, Stefania Clemente, Antonio Varallo iD, Mariano Scaglione iD, Alberto Cuocolo iD, Michele Klain iD

Current Oncology · 2024

DOI: 10.3390/curroncol31090416 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Leandra Piscopo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Biomedical Sciences, University of Naples, Federico II, 80131 Naples, Italy. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms, Octreotide, Intestinal Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of the present study was to evaluate the safety and efficacy of radionuclide therapy with [177Lu]Lu-DOTA-TATE according to our single center experience at the University of Naples Federico II. For the present analysis, we considered 21 patients with progressive, advanced, well-differentiated G1 and G2 in patients with gastro-entero-pancreatic (GEP) neuroendocrine tumors (NETs) treated with [177Lu]Lu-DOTA-TATE according to the decisions of a multidisciplinary team. All patients underwent four cycles of 7–8 GBq of [177Lu]Lu-DOTA-TATE every 8 weeks. A whole-body scan (WBS) was performed 4, 48, and 168 h after each treatment. The dosimetry towards the organ at risk and target lesions was calculated. For each patient, renal and bone marrow parameters were evaluated before, during, and 3 months after the end of the treatment. Follow-up data were obtained and RECIST criteria were considered as the endpoint. Among 21 patients enrolled (mean age 65 ± 9 years); 17 (81%) were men and the small intestine was the most frequent location of disease (n = 12). A mild albeit significant variation (p < 0.05) in both platelets and white blood cell counts among all time points was observed, despite it disappearing 3 months after the end of the therapy. According to the RECIST criteria, 11 (55%) patients had a partial response to therapy and 8 (40%) had stable disease. Only one (5%) patient had disease progression 4 months after treatment. Our data confirm that [177Lu]Lu-DOTA is safe and effective in controlling the burden disease of G1/G2 GEP-NETs patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsPancreatic NeoplasmsOctreotideIntestinal NeoplasmsStomach NeoplasmsHumansMaleFemaleAgedMiddle AgedOrganometallic CompoundsReceptors, PeptideRadiopharmaceuticalsTreatment Outcome

Stichwörter der Autor:innen

[177Lu]Lu-DOTA-TATEdosimetrygastro-entero-pancreatic neuroendocrine tumors (GEP-NETs)multidisciplinary teampeptide receptor radionuclide therapy (PRRT)

Substanzen

OctreotideOrganometallic CompoundsReceptors, Peptidelutetium Lu 177 dotatateRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Advanced Biomedical Sciences, University of Naples, Federico II, 80131 Naples, Italy.
  • Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.

ORCID-Profile: Emilia Zampella, Fabio Volpe, Antonio Varallo, Mariano Scaglione, Alberto Cuocolo, Michele Klain

Zitieren

APA

Piscopo, L., Zampella, E., Volpe, F., Gaudieri, V., Nappi, C., Di Donna, E., Clemente, S., Varallo, A., Scaglione, M., Cuocolo, A., & Klain, M. (2024). The Safety and Efficacy of Peptide Receptor Radionuclide Therapy for Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Single Center Experience. Current Oncology. https://doi.org/10.3390/curroncol31090416

Vancouver

Piscopo L, Zampella E, Volpe F, Gaudieri V, Nappi C, Di Donna E, et al. The Safety and Efficacy of Peptide Receptor Radionuclide Therapy for Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Single Center Experience. Current Oncology. 2024. doi:10.3390/curroncol31090416

BibTeX
@article{Piscopo2024,
  author = {Piscopo, Leandra and Zampella, Emilia and Volpe, Fabio and Gaudieri, Valeria and Nappi, Carmela and Di Donna, Erica and Clemente, Stefania and Varallo, Antonio and Scaglione, Mariano and Cuocolo, Alberto and Klain, Michele},
  title = {The Safety and Efficacy of Peptide Receptor Radionuclide Therapy for Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Single Center Experience},
  journal = {Current Oncology},
  year = {2024},
  doi = {10.3390/curroncol31090416}
}
Kostenlos starten →